MedTrace Logo

Assessment of Suicidality in Epilepsy - Rating Tools

NCT01085461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2012-03-05

No results posted yet for this study

Summary

This will be a cross-sectional study enrolling 200 outpatients/inpatients with treatment resistant partial epilepsy for at least two years, receiving 1-3 AEDS.

The study will consist of one or two visits, each lasting 1-2 hours. All subjects will complete Visit 1. Twenty five percent of the subjects will return for Visit 2. The study will assess the prevalence of depression and suicidal thoughts and the feasibility of using the proposed psychiatric rating scales in future epilepsy clinical trials. This study will also provide an estimate of the proportion of patients with epilepsy (PWE) who may be ineligible for future trials.

Conditions

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    collaborator INDUSTRY

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Supernus Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • UCB Pharma

    collaborator INDUSTRY

  • Upsher-Smith Laboratories

    collaborator INDUSTRY

  • The Epilepsy Study Consortium

    lead OTHER

Principal Investigators

  • Jacqueline French, M.D. · NYU Langone Medical Center

  • Andres Kanner, M.D. · Rush University Medical Center

  • Dale Hesdorffer, PhD, MPH · Columbia University

  • Kelly Posner, PhD · Columbia University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01085461 on ClinicalTrials.gov